Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
September 10, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents for the treatment of relapsed PTCL and...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024 16:05 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D.,...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
August 06, 2024 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels Consistent with ITK Inhibition Mechanism of...
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
August 01, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL,...
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
July 31, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases
July 25, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
Data demonstrated in vitro and in vivo ITK inhibition with soquelitinib induced switching of proinflammatory Th17 cells into anti-inflammatory Treg cells Publication confirms and extends...
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
May 30, 2024 16:02 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
May 06, 2024 16:01 ET
|
Corvus Pharmaceuticals, Inc.
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib Registration Phase 3 Trial in Peripheral T Cell...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
May 02, 2024 16:02 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
May 02, 2024 08:30 ET
|
Corvus Pharmaceuticals, Inc.
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today...